Arvinas, Inc.

Arvinas, Inc. Earnings Recaps

ARVN Health Care 2 recaps
Q1 2026 May 13, 2026

Arvinas shares ticked up modestly by 2.2% following approval and licensing of VEPPANU but the market’s tepid response suggests investors remain cautious about near-term commercial execution and longer-term pipeline visibility.

Key takeaways
  • The FDA approved VEPPANU, the first PROTAC degrader approved for ESR1-mutant, ER+/HER2- advanced breast cancer, marking a milestone for Arvinas’ platform.
  • Arvinas licensed global commercialization, development, and manufacturing rights for VEPPANU to Rigel Pharmaceuticals, opting to focus internal resources on pipeline innovation.
  • Phase 1 data for ARV-102 in Parkinson’s disease demonstrated approximately 50% reductions in cerebrospinal fluid LRRK2 at day 14 sustained through day 28, alongside dose-dependent biomarker improvements with good tolerability.
  • The company maintains four ongoing Phase 1 clinical programs and a disciplined capital allocation approach but provided limited detail on near-term milestones or revenue guidance from VEPPANU.
  • The modest stock movement implies investor reservations on commercial visibility and execution risks despite scientific validation and platform progress.
Full recap
Q3 2025 Nov 6, 2025

Arvinas reported a productive third quarter in 2025, characterized by key clinical updates and advancements in their therapeutic pipeline, positioning the company favorably for upcoming milestones.

Key takeaways
  • Significant clinical data announced for ARV-102, an oral LRRK2 degrader, showing strong tolerability and promising biomarker reductions in ongoing Phase I trials.
  • Preclinical data for ARV-806 and ARV-027 highlight progress in developing therapies targeting KRAS G12D mutations and spinal bulbar muscular atrophy, respectively.
  • Vepdegestrant's NDA is under FDA review with a PDUFA date set for June 5, 2026; plans to partner with Pfizer for commercialization are underway.
  • Strong cash position extends financial runway into the second half of 2028, providing strategic flexibility for ongoing and future projects.
Full recap